Core Viewpoint - Houston American Energy Corp. has successfully completed a registered direct offering, raising approximately $8 million at a price of $3.50 per share, indicating strong market confidence in the company's strategic direction towards renewable energy [1][2][3]. Financing Details - The offering was supported by Tier-1 institutional investors, reflecting confidence in the company's transition to circular fuels and renewable energy production [2]. - The net proceeds will be allocated to complete Phase 1 of the Cedar Port Renewable Energy Complex, advance the Final Investment Decision for a waste-plastics-to-fuels facility, repay a convertible note, and for general corporate purposes [2][3]. Strategic Growth - The CEO highlighted that this transaction is a significant milestone in the company's long-term growth strategy, enhancing its capital position and financial flexibility [3]. - Recent achievements include the groundbreaking of the Cedar Port Renewable Energy Complex and the integration of the circular-fuels platform acquired from Abundia Global Impact Group, which supports long-term value creation [3][6]. Regulatory Compliance - The securities were issued under an existing shelf registration statement effective from November 3, 2025, with a prospectus supplement filed with the SEC [4].

Core Insights - NeoVolta Inc. has announced a $13 million private placement financing led by Infinite Grid Capital to support its growth and manufacturing expansion in the U.S. [1][2] Financing and Manufacturing Initiative - The investment aims to provide immediate and future capital for NeoVolta's domestic manufacturing initiative, including a memorandum of understanding with third parties to establish a battery energy storage manufacturing facility in Georgia [2][3] - The proposed facility is designed for an initial annual capacity of approximately 2 GWh, focusing on utility-level and commercial & industrial battery energy storage systems, which will expand NeoVolta's market and revenue opportunities [3] Financial Position and Growth - The capital raised will significantly enhance NeoVolta's financial position, improving liquidity and addressing working capital needs to support ongoing growth initiatives [3] - NeoVolta and IGC plan to evaluate future commercial opportunities, including potential offtake arrangements that align with IGC's grid-scale pipeline [4] Strategic Partnership - The partnership with Infinite Grid Capital is seen as a long-term strategic investment, with IGC committing $10 million to support NeoVolta's manufacturing plans and commercial scaling [5] - Both companies will provide updates on key milestones and the evolution of NeoVolta's manufacturing and market initiatives as the relationship develops [5]

BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster Presentation Date & Time: Wednesda ...

Core Insights - Biodexa Pharmaceuticals has activated its first European site for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP), marking a significant milestone in expanding treatment options for European patients [1][2] Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, including eRapa for FAP and other therapies for type 1 diabetes and rare brain cancers [7] Clinical Trial Details - The Serenta trial is a randomized, double-blind, placebo-controlled study designed to assess the efficacy of eRapa in preventing disease progression in FAP patients, who face a near-100% risk of colorectal cancer by age 50 if untreated [3][4] - The trial began enrolling patients in the US in August 2025, with nine additional European sites expected to activate in the next 2-3 months across the Netherlands, Spain, Denmark, and Italy [3] Treatment Context - FAP is a rare inherited disorder characterized by the development of numerous colorectal polyps, leading to a significant unmet need for effective, less invasive therapies, as current standard care involves surgical resection [4] - eRapa, a proprietary oral formulation of rapamycin, is an mTOR inhibitor that targets the over-expression of mTOR in FAP polyps, providing a rationale for its use in treatment [5][8] Funding and Support - The advancement of the Serenta trial has been supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas, alongside collaborations with Emtora Biosciences and Precision for Medicine [2][6]

Core Insights - Waton Financial Limited has announced an expanded strategic partnership with Panda AI to explore the formation of a joint venture, enhancing their collaboration in AI-driven securities trading [1][2][3] - The partnership aims to leverage Panda AI's capabilities to improve Waton's DePearl™ core AI technology and trading agents, promoting automated trading strategies globally [1][2] - This collaboration is expected to strengthen Waton's position as a key infrastructure provider in the AI trading economy, creating new revenue opportunities and enhancing institutional client engagement [2][3] Company Overview - Waton Financial Limited operates primarily through its subsidiaries in Hong Kong, offering a range of financial services including securities brokerage, asset management, and software licensing [4] - The company emphasizes a technology-driven and customer-centric approach to deliver innovative financial solutions [4] Strategic Goals - The partnership with Panda AI reflects Waton's commitment to transforming traditional finance through AI, aiming for institutional-scale adoption of AI trading solutions [3] - The potential joint venture may expand Waton's AI product offerings, including the InfoMan investor relations agent, reinforcing its competitive edge in the fintech sector [3]

Core Insights - The automotive industry is increasingly interested in SPD-SmartGlass technology, transitioning from an emerging concept to an essential feature for modern vehicles, enhancing comfort, safety, and energy efficiency [2][4][10] Industry Interest and Adoption - The ECV Automotive Glazing Summit highlighted the strong interest in SPD-SmartGlass, with automakers actively evaluating or using the technology in various vehicle programs, including premium and next-generation electric vehicles [4][10] - Automakers are seeking proven, production-ready dynamic glazing solutions, with SPD-SmartGlass offering immediate tint response and energy savings, having been used in tens of thousands of vehicles since 2011 [5][10] Collaboration and Integration - The summit emphasized the importance of collaboration among film developers, glass processors, and OEM engineering teams to ensure seamless integration of dynamic glazing into vehicle platforms [6][9] - Research Frontiers engaged in discussions to address cost targets and optimize system performance, fostering productive dialogue within the industry [6][9] Technology Comparison - There is a need for clarity among different variable-tint technologies, with SPD-SmartGlass noted for its fast switching speed (1-3 seconds) and optical consistency, outperforming slower electrochromic solutions [6][10] - SPD-SmartGlass provides significant advantages in energy efficiency, comfort, and safety, resonating with OEMs evaluating technologies for their upcoming vehicle platforms [7][10] Features and Benefits - SPD-SmartGlass technology offers numerous benefits, including energy savings, increased driving range, improved passenger experience, and enhanced safety [7][11] - Key performance metrics include a 1-2 second switching speed, 99%+ UV blocking, up to 95% heat rejection, and a reduction in cabin temperature by approximately 10°C [11] Summit Outcomes - The summit concluded with strong interest from automakers for follow-up demonstrations and technical workshops, indicating a trend towards accelerated adoption of SPD-SmartGlass technology [9][10]

Core Insights - CytoDyn Inc. is set to present clinical data at the San Antonio Breast Cancer Symposium, showcasing sustained remission in patients with metastatic triple-negative breast cancer (mTNBC) following treatment with leronlimab and immune checkpoint inhibitors [1][3] Company Overview - CytoDyn is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in various cancers, including mTNBC and colorectal cancer [1][6] Clinical Data Presentation - Dr. Milana V. Dolezal from Stanford University will present a poster detailing the prolonged survival of mTNBC patients treated with leronlimab in combination with PD-L1/PD-1 immune checkpoint inhibitors, highlighting the upregulation of PD-L1 levels [2][9] - The poster presentation is scheduled for December 12, 2025, from 12:30 PM to 2:00 PM CST at the Exhibit Hall [9] Treatment Efficacy - The use of leronlimab has been associated with increased PD-L1 levels, which may enhance the efficacy of immune checkpoint inhibitors in mTNBC patients, particularly those with low PD-L1 expression [2][3]

Core Points - Digital Ally, Inc. announced the full lineup for the 2026 Country Stampede Music Festival, featuring headliners Treaty Oak Revival, Zach Top, and Rascal Flatts [1][2] - The festival aims to showcase both established artists and emerging talent, with a diverse support lineup including Wyatt Flores, Scotty McCreery, and others [3] - The event will take place on June 25, 26, and 27, 2026, at the Azura Amphitheater in Bonner Springs, Kansas, with various ticketing options available [6] Group 1 - The 2026 Country Stampede will include a pre-party and late-night after parties to enhance fan experiences [4] - An annual Battle of the Bands competition will allow rising artists to compete for a chance to open the Main Stage [5] - Kustom Entertainment emphasizes community engagement and aims to provide a platform for emerging artists alongside established headliners [6] Group 2 - Digital Ally, Inc. operates through subsidiaries engaged in video solution technology, healthcare revenue cycle management, and event production [7] - Kustom Entertainment, a subsidiary of Digital Ally, specializes in producing live entertainment experiences, with the Country Stampede being a flagship event [7]

Core Viewpoint - Wrap Technologies, Inc. has announced that the Rio Grande City Police Department in Texas will implement the BolaWrap® 150 device and the WrapReady™ program to enhance non-lethal response capabilities amid increasing operational pressures along the U.S.–Mexico border [1][4]. Group 1: Agreement Details - The agreement includes full WrapReady onboarding for 12 officers, covering equipment, multi-year support, and instructor-level certification, marking the first deployment in a Texas border community [2]. - The WrapReady program aims to reduce friction in deployment, training, and long-term utilization of the BolaWrap® ecosystem, focusing on safer engagements and continuous development of agency tactics and policy [4][5]. Group 2: Operational Context - Rio Grande City is located in a high-traffic area of the U.S.-Mexico border, where local agencies frequently engage in multi-jurisdictional operations related to narcotics interdiction, human smuggling, and mental health crises, necessitating non-lethal response tools [3]. - The adoption of the WrapReady program reflects a national trend among law enforcement agencies re-evaluating pain-compliance tools and opting for non-lethal options like BolaWrap as first-resort tools in complex encounters [4]. Group 3: Product Overview - Wrap Technologies offers a comprehensive public safety portfolio, including the BolaWrap 150 device, WrapReality™ training platform, and WrapVision™ body-worn camera system, all designed to enhance public safety and operational efficiency [6][7]. - The BolaWrap 150 is a non-pain-based compliance tool that helps officers manage non-compliant subjects without resorting to higher-force options, thereby reducing injury risks [9].

Core Insights - Profusa, Inc. is set to present a Late Breaking Clinical Trial Update on its Lumee™ Oxygen tissue monitoring platform at the Paris Vascular Insights (PVI) 2025 conference, highlighting its innovative technology for continuous monitoring of tissue oxygen in patients with peripheral artery disease [1][2] - The Lumee technology allows for real-time measurement of tissue oxygen levels directly within the body, representing a significant advancement in biochemistry monitoring for both clinical and home use [2][3] - Profusa aims to provide personalized biochemical data through its long-lasting, injectable biosensors, which are designed to deliver actionable medical-grade information for both personal and medical applications [3] Presentation Details - The presentation titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" will be delivered by Dr. Peter Schneider on December 13, 2025, at 1pm CET [2] - The event will take place at the Carrousel du Louvre in Paris, France, showcasing the latest innovations in vascular and endovascular surgery [2] Company Overview - Profusa is based in Berkeley, California, and is recognized for its pioneering work in developing tissue-integrated sensors that continuously transmit reliable biochemical data [3] - The company is led by a team of experienced professionals and aims to create a new generation of affordable biosensors that enhance patient care through personalized data [3]